NECTIN4 and cholangiocarcinoma: The highest prevalence of NECTIN4 amplifications was found in bladder cancer (BLCA, 17%), cholangiocarcinoma (CHOL, 14%), hepatocellular carcinoma (LIHC, 12%), breast cancer (BRCA, 9%), and lung adenocarcinoma (LUAD, 7%).